Generex Biotechnology (GNBT) Return on Assets ROA from the third quarter of 2021 to third quarter of 2020 and for the year 2021, Average High and Low, Fundamental Ratios from Apr 30 2021 to Apr 30 2020 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Generex Biotechnology Corp  (GNBT)


Generex Biotechnology's ROA from the third quarter of 2021 to the third quarter of 2020 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Generex Biotechnology's ROA in the third quarter of 2021?
Generex Biotechnology Corp recorded a cumulative net loss of $-37 million during 12 months ending in the third quarter of 2021, resulting in a negative return on assets (ROA) of -80.29%.

However, within the Healthcare sector 810 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Apr 30 2021 quarter, so far to 4563, from total ROA ranking in the second quarter of 2021 at 5154.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Apr 30 2021)
III. Quarter		 (Jan 31 2021)
II. Quarter		 (Oct 31 2020)
I. Quarter		 (Jul 31 2020)
IV. Quarter		 (Apr 30 2020)
III. Quarter
Y / Y Total Assets Change -11.51 % -12.65 % -12.16 % -8.57 % -3.96 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -37 -51 -33 -28 -21
Return On Assets (TTM) -80.29 % -107.38 % -68.49 % -55.58 % -41.32 %
GNBT's Total Ranking # 4563 # 5154 # 4354 # 4249 # 4121
Total Assets (TTM) in million 46 46 46 45 52
Seq. Total Assets Change 0.91 % -0.82 % 1.11 % -12.55 % -0.4 %
Seq. Net Income Change - - - - -

GNBT's 5 Years Annual ROA >> Back to GNBT Management Effectiveness >> Compare GNBT ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 403
Sector # 811
Overall # 4427

Return On Assets Statistics
High Average Low
193.99 %
-39.09 %
-323.15 %
(Jul 31 2018)   (Jul 31 2017)





Financial Statements
Generex Biotechnology's Assets $ 46 million GNBT's Balance sheet
Generex Biotechnology's Income $ 8 million Quarterly GNBT's Income Statement
GNBT's Income by Division See GNBT's Income by Division



Annual Return On Assets (Jul 31 2020)
FY 2020		 (Jul 31 2019)
FY 2019		 (Jul 31 2018)
FY 2018		 (Jul 31 2017)
FY 2017		 (Jul 31 2016)
FY 2016
Y / Y Total Assets Change -8.57 % 172.74 % -6.98 % 74365.79 % -98.89 %
Total Assets in million 45 50 18 20 0
Y / Y Net Income Change - - - - -
Net Income in million -32 -8 37 -63 -3
Annual Return On Assets -71.48 % -15.46 % 201.77 % -323.02 % -12267.29 %

GNBT's 5 Years Annual ROA >> Back to GNBT Management Effectiveness >> Compare GNBT ROA to its Competitors



More Return On Assets Ratios
GNBT's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
GNBT's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for GNBT's Competitors
Subscribers only: Roa for Generex Biotechnology's Suppliers
Subscribers only: Return On Assets for GNBT's Customers

You may also want to know
GNBT's Roi GNBT's Inventory Turnover Ratio GNBT's Growth Rates GNBT's Dividend Comparisons
GNBT's Profitability Ratios GNBT's Asset Turnover Ratio GNBT's Dividend Growth
GNBT's Roe GNBT's Valuation Ratios GNBT's Financial Strength Ratios GNBT's Dividend Payout Ratio



Companies with similar Return On Assets at Apr 30 2021, within Healthcare Sector ROA

Date modified: 2026-09-08T15:10:18+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.